Retrophin (RTRX) and Its Competitors Financial Review
Retrophin (NASDAQ: RTRX) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Retrophin to related companies based on the strength of its institutional ownership, valuation, dividends, analyst recommendations, profitability, earnings and risk.
This table compares Retrophin and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.9% of Retrophin shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings and target prices for Retrophin and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Retrophin currently has a consensus target price of $36.00, suggesting a potential upside of 70.37%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.74%. Given Retrophin’s stronger consensus rating and higher possible upside, research analysts clearly believe Retrophin is more favorable than its peers.
Valuation & Earnings
This table compares Retrophin and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Retrophin||$133.59 million||-$47.90 million||-13.99|
|Retrophin Competitors||$284.28 million||$34.29 million||134.95|
Retrophin’s peers have higher revenue and earnings than Retrophin. Retrophin is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Retrophin has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Retrophin’s peers have a beta of 6.22, indicating that their average share price is 522% more volatile than the S&P 500.
Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.